Andrew Goldberg Sells TARS Shares
Andrew Goldberg sold 2,954 shares of TARS on June 12, 2026.
Key Points
- Andrew Goldberg sold 2,954 shares of TARS on June 12, 2026, without a planned transaction code.
- TARS shares recently traded at $61.85, with peers like Deep Track Capital and BlackRock adjusting their holdings.
- Analysts from HC Wainwright & Co. and Oppenheimer maintain a 'buy' rating, with price targets of $88 and $105 respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Andrew Goldberg sold 2,954 shares of TARS on June 12, 2026. The transaction wasn't part of a pre-planned trading arrangement, often referred to as a Rule 10b5-1 plan. While the sale was recorded, the exact value of the transaction wasn't disclosed.
Other Institutional Activity in TARS
In recent movements among institutional investors, Deep Track Capital grew its holdings in TARS by 595,966 shares, bringing its total to 3.6 million shares valued at about $252.54 million. BlackRock, Inc. reduced its position by 237,945 shares, now holding 3,552,612 shares worth around $249.22 million. RTW Investments, LP made a modest increase of 10,705 shares, ending with 3,346,025 shares valued at approximately $234.72 million. Meanwhile, Paradigm Biocapital Advisors LP maintained its position with 2,562,154 shares valued at $179.74 million. Janus Henderson Group PLC increased its stake by 310,638 shares, totaling 2,240,963 shares valued at around $157.22 million.
Tarsus Pharmaceuticals, Inc. Stock Down 13.8%
TARS shares recently traded at $61.85. The company has been a point of interest for several institutional investors adjusting their holdings. The stock's performance and valuation continue to attract attention from both institutional investors and analysts.
$TARS stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Tarsus Pharmaceuticals, Inc.
Alongside Andrew Goldberg's sale, several other insiders were active on June 12, 2026. Bhaskar Chaudhuri sold 2,954 shares, while Wendy Yarno both bought and sold 2,954 shares. William Link also bought 2,954 shares, and Scott Morrison sold the same amount. None of these transactions were part of a planned trading program.
Analysts Set New Price Targets
On May 4, 2026, HC Wainwright & Co. reiterated a 'buy' rating for TARS with a price target of $88. Earlier in the year, on February 25, 2026, Oppenheimer maintained its 'buy' rating with a higher target of $105. Guggenheim also maintained its 'buy' rating with a target of $90.
Bottom Line
Andrew Goldberg's recent sale of TARS shares is one of several insider transactions that have occurred. Institutional investors like Deep Track Capital and BlackRock have also been adjusting their positions, reflecting varied strategies. Analysts maintain positive outlooks with 'buy' ratings, suggesting continued interest in TARS. Note that insider transactions and institutional holdings are backward-looking and may not reflect current positions.
Get Tarsus Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $TARS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.